Nipah Vaccine Safe, Immune Response in Phase 1 Trial: Lancet Study

A new Nipah virus vaccine candidate, HeV-sG-V, has demonstrated safety and generated a strong immune response in a Phase 1 clinical trial, according to a study published in The Lancet. This represents a significant step towards preventing the deadly infection, particularly for regions like India frequently affected by outbreaks.

• Experimental Nipah vaccine, HeV-sG-V, proved safe in Phase 1 trial.
• Study published in The Lancet confirmed vaccine generates immune response.
• Two doses effectively produced antibodies in 192 healthy adults.
• Mild injection site pain was the most common side effect reported.
• Indian scientists hail results as 'milestone,' urge Phase 2 trials.
• Nipah virus is a WHO high-priority pathogen with high fatality rates.

Read the full story on Quick Digest.